The present invention relates to a process for the asymmetric oxidation of nucleophilic organic compounds, particularly metal-free, with peroxide compounds in the presence of a chiral Brnsted acid catalyst. In one detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral imidodiphosphate catalyst. In another detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral phosphoric acid catalyst.

The present invention relates to a process for the asymmetric oxidation of nucleophilic organic compounds, particularly metal-free, with peroxide compounds in the presence of a chiral Brnsted acid catalyst. In one detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral imidodiphosphate catalyst. In another detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral phosphoric acid catalyst.

The present disclosure relates to acaricide, specifically to a kind of biphenyl compounds and uses thereof. The general formula I is as follows: ##STR00001##
wherein: each substituent is defined as that in the description. The compounds of the general formula I show high acaricidal activities and can be used for controlling various harmful mites.

The present disclosure relates to acaricide, specifically to a kind of biphenyl compounds and uses thereof. The general formula I is as follows: ##STR00001##
wherein: each substituent is defined as that in the description. The compounds of the general formula I show high acaricidal activities and can be used for controlling various harmful mites.

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: ##STR00001##
wherein, each symbol is explained in greater detail in the specification.

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: ##STR00001##
wherein, each symbol is explained in greater detail in the specification.

Provided are polymorphic and salt forms of (1S,3S)N.sup.1(5-(pentan-3-yl)pyrazolo[1,5-]pyrimidin-7-yl) cyclopentane-1,3-diamine. Provided are polymorphic forms of the free base of the compound along with polymorphic forms of salts of the compound, including tosylate salts, oxalate salts, fumarate salts, camsylate salts, citrate salts, hydrochloride salts, and naphthalene-1,5-disulfonic acid salts. Such forms have been characterized by X-ray diffraction (XRD), differential scanning calorimetry (DSC), and thermogravimetric analysis coupled to mass spectrometry (TGA-MS). Such polymorphic and salt forms can have desirable solubility, dissolution, and pharmacokinetic properties.

Provided are polymorphic and salt forms of (1S,3S)N.sup.1(5-(pentan-3-yl)pyrazolo[1,5-]pyrimidin-7-yl) cyclopentane-1,3-diamine. Provided are polymorphic forms of the free base of the compound along with polymorphic forms of salts of the compound, including tosylate salts, oxalate salts, fumarate salts, camsylate salts, citrate salts, hydrochloride salts, and naphthalene-1,5-disulfonic acid salts. Such forms have been characterized by X-ray diffraction (XRD), differential scanning calorimetry (DSC), and thermogravimetric analysis coupled to mass spectrometry (TGA-MS). Such polymorphic and salt forms can have desirable solubility, dissolution, and pharmacokinetic properties.

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: ##STR00001##
(wherein, each symbol is explained in greater detail in the specification).

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: ##STR00001##
(wherein, each symbol is explained in greater detail in the specification).